Comparative Pharmacology
Head-to-head clinical analysis: EMVERM versus VANSIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMVERM versus VANSIL.
EMVERM vs VANSIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Vansil (oxamniquine) is an antischistosomal agent that increases calcium permeability in susceptible schistosomes, leading to muscle contraction, paralysis, and eventual death of the parasite. It is specifically active against Schistosoma mansoni.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
20 mg/kg orally twice daily for 1 day (maximum single dose: 1 g).
None Documented
None Documented
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Terminal elimination half-life is approximately 85-105 hours in patients with normal renal function, allowing once-daily dosing; prolonged in renal impairment
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Primarily renal (70-80% as unchanged drug) with minor biliary/fecal elimination (15-20%) and hepatic metabolism (10-15%)
Category C
Category C
Anthelmintic
Anthelmintic